Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · MDGL · as of Jun 8, 2026
Activity summary
Buy transactions
54
P-Purchase only
Sell transactions
245
12 Months
Buy/Sell ratio
0.22
Buy/Sell (by trades)
Overall sentiment
Madrigal Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
MDGL insider buying and selling by quarter
MDGL insider selling · MDGL insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · MDGL ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
MDGL executive sell shares · MDGL board member insider trading · MDGL insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Soergel David Chief Medical Officer | Sale | 1,042 | $517K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 40 | $20K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 320 | $163K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 151 | $77K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 610 | $312K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 439 | $225K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 40 | $21K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 343 | $177K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 657 | $339K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 723 | $374K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 1,497 | $775K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 782 | $406K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 80 | $42K | Form 4 |
| May 18, 2026 | Soergel David Chief Medical Officer | Sale | 844 | $435K | Form 4 |
| Mar 4, 2026 | Dier Mardi EVP and CFO | Award | 5,215 | — | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 646 | $279K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $17K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 420 | $179K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $34K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 160 | $69K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $17K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 120 | $52K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 116 | $50K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 160 | $69K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $35K | Form 4 |
Soergel David
Chief Medical Officer
Date
Jun 1
Shares
1,042
Price
$495.74
Value
$517K
Soergel David
Chief Medical Officer
Date
May 18
Shares
844
Price
$515.90
Value
$435K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About MDGL insider trading
MDGL insider trades
Madrigal Pharmaceuticals, Inc. (MDGL) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including FRIEDMAN PAUL A (Director), Levy Richard S (Director), Dier Mardi (EVP and CFO). Over the past 12 months, 5 insiders have filed transactions with the SEC. MDGL insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Madrigal Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
MDGL insider trading · 5 questionsThe insiders of Madrigal Pharmaceuticals, Inc. (MDGL) include executives and directors such as FRIEDMAN PAUL A (Director), Levy Richard S (Director), Dier Mardi (EVP and CFO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026